null
E-publication E-publication

Combatting Treatment-Naïve, Extensive-Stage SCLC With Novel Immunotherapeutic Strategies


Released:
4/12/19
Expires:
4/11/20

Maximum Credits:

0.5
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

E-publication E-publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.
Released:
4/12/19

Expires:
4/11/20

Maximum Credits:
0.5
E-publication E-publication
By clicking "Continue," you are confirming that you have reviewed the CME information and read, understood, and unconditionally agreed to the Privacy Notice and Terms of Use.

Released:
4/12/19
Expires:
4/11/20


Maximum Credits:
0.5


Overview: This accredited publication highlights current evidence regarding the use of immune checkpoint inhibitors (ICIs) in combination with standard chemotherapy for patients with treatment-naïve, extensive-stage small cell lung cancer (ES-SCLC). It also examines the implications of incorporating ICIs into first-line ES-SCLC therapy on clinical management and approaches for monitoring and managing immune-related adverse events. In addition, this activity features audio clips of faculty insight and feedback from a Med-IQ survey of medical oncologists to highlight the challenges that community providers face in maintaining evidence-based practice habits in ES-SCLC.

CME Information:

Faculty
Leora Horn, MD, MSc
Ingram Associate Professor of Cancer Research
Vice Chairman for Faculty Development
Director, Thoracic Oncology Program
Vanderbilt University Medical Center
Nashville, TN
 
Stephen V. Liu, MD
Associate Professor of Medicine
Lombardi Comprehensive Cancer Center
Georgetown University Medical Center
Washington, DC

Activity Planners
Erin Grothey, MS
Clinical Content Manager
Med-IQ
Baltimore, MD
 
Laura Rafferty, ELS
Managing Editor
Med-IQ
Baltimore, MD
 
Samantha Gordon
CME Specialist
Med-IQ
Baltimore, MD
 
Kathryn Schaefer, MSN, RN, CPHRM
Senior Manager, Accreditation and Compliance
Med-IQ
East Lansing, MI
 
Writer
Katherine Stevens-Favorite, PhD
Montpelier, VT
 
Learning Objectives
Upon completion, participants should be able to:

  • Assess clinical data on immunotherapies for patients with treatment-naïve, extensive-stage SCLC
  • Apply clinical evidence about novel immunotherapeutic strategies to the treatment decision-making process for patients with treatment-naïve, extensive-stage SCLC
  • Develop strategies to adequately assess treatment response and appropriately manage immune-related toxicities in patients with extensive-stage SCLC receiving treatment with immune checkpoint inhibitors

Target Audience
This activity is intended for medical oncologists, radiation oncologists, and oncology-focused nurse practitioners and physician assistants.
 
Statement of Need
Rapidly evolving clinical evidence on the use of immune checkpoint inhibitors (ICIs) in various malignancies has demonstrated their ability to improve clinical outcomes. A report from a randomized clinical trial comparing the addition of atezolizumab, which blocks the programmed cell death-ligand 1 (PD-L1), and placebo to carboplatin/etoposide in patients with treatment-naïve, extensive-stage small cell lung cancer (ES-SCLC) found that it prolonged progression-free and overall survival. Based on these data, the United States Food and Drug Administration (FDA) granted priority review for the atezolizumab-chemotherapy regimen in this setting, with an expected decision date of March 18, 2019, and the National Comprehensive Cancer Network updated its guidelines (v1.2019) to include this regimen as preferred therapy for ES-SCLC. Additionally, reports from several large randomized trials evaluating ICIs that block the action of PD-L1, programmed cell death 1 (PD-1), and/or cytotoxic T-lymphocyte antigen (CTLA-4) as first-line therapy for ES-SCLC are eagerly awaited; results are expected in 2019 and 2020. Due to this rapid release of clinical evidence, oncologists, nurse practitioners, and physician assistants must be aware of the effectiveness and safety of this regimen and the impact of incorporating ICIs into first-line ES-SCLC therapy on existing treatment paradigms. Furthermore, providers must be familiar with appropriate strategies for assessing treatment response as well as identifying and effectively managing immune-related adverse events associated with ICIs.

Providership Statement
Provided by Med-IQ.

Accreditation/Designation Statements
Med-IQ is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Med-IQ designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurse practitioners, physician assistants, and other healthcare professionals who successfully complete the activity will receive a Statement of Participation indicating the maximum credits available.

Medium/Method of Participation
This CME activity consists of a 0.5-credit online publication. To receive credit, read the introductory CME material, read the publication, and complete the post-survey, evaluation, attestation, and post-test, answering at least 70% of the post-test questions correctly.
 
Initial Release Date: April 12, 2019
Expiration Date: April 11, 2020
Estimated Time to Complete This Activity: 30 minutes

Disclosure Policy
Med-IQ requires any person in a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as those in any amount occurring within the past 12 months, including those of a spouse/life partner, that could create a conflict of interest (COI). Individuals who refuse to disclose will not be permitted to contribute to this CME activity in any way. Med-IQ has policies in place that will identify and resolve COIs prior to this educational activity. Med-IQ also requires faculty to disclose discussions of investigational products or unlabeled/unapproved uses of drugs or devices regulated by the US Food and Drug Administration.
 
Disclosure Statement
The content of this activity has been peer reviewed and has been approved for compliance. The faculty and contributors have indicated the following financial relationships, which have been resolved through an established COI resolution process, and have stated that these reported relationships will not have any impact on their ability to give an unbiased presentation. 
 
Leora Horn, MD, MSc
Consulting fees/advisory boards: AbbVie Inc., AstraZeneca, Bristol-Myers Squibb, EMD Serono, Inc., Genentech, Incyte Corporation, Merck & Co., Inc., Xcovery
 
Stephen V. Liu, MD
Consulting fees/advisory boards: AstraZeneca, Bristol-Myers Squibb, Celgene Corporation, Genentech, Heron Therapeutics, Inc., Lilly USA, LLC, Merck & Co., Inc., Pfizer, Inc., Regeneron Pharmaceuticals, Inc., Taiho Pharmaceutical Co., Ltd., Takeda Pharmaceuticals North America, Inc.
Contracted research: AstraZeneca, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Clovis Oncology, Corvus Pharmaceuticals, Esanex, Genentech, Lilly USA, LLC, Lycera Corp., Merck & Co., Inc., Molecular Partners, OncoMed Pharmaceuticals, Inc., Pfizer, Inc., Rain Therapeutics, Threshold Pharmaceuticals, Inc.

Katherine Stevens-Favorite, PhD
Other: Atara Biotherapeutics, Halozyme Therapeutics, Incyte Corporation, Portola Pharmaceuticals, Inc., Takeda Pharmaceuticals North America, Inc.

The peer reviewers and other activity planners have no financial relationships to disclose.

Statement of Evidence-Based Content
Educational activities that assist physicians in carrying out their professional responsibilities more effectively and efficiently are consistent with the ACCME definition of continuing medical education (CME). As an ACCME-accredited provider of CME, it is the policy of Med-IQ to review and ensure that all the content and any recommendations, treatments, and manners of practicing medicine in CME activities are scientifically based, valid, and relevant to the practice of medicine. Med-IQ is responsible for validating the content of the CME activities it provides. Specifically, (1) all recommendations addressing the medical care of patients must be based on evidence that is scientifically sound and recognized as such within the profession; (2) all scientific research referred to, reported, or used in CME in support or justification of a patient care recommendation must conform to generally accepted standards of experimental design, data collection, and analysis.
 
Med-IQ is not liable for any decision made or action taken in reliance upon the information provided through this activity.

Contact Information        
For questions or comments about this activity, please contact Med-IQ. Call (toll-free) 866 858 7434 or email info@med-iq.com.          
                      
System Requirements
Desktop

Mobile

  • Operating system - Med-IQ supports the current operating system, plus two prior releases:
    • Android (eg, Samsung Galaxy)
    • Apple (eg, iPhone/iPad)
  • Browsers - Med-IQ supports the default browser for the applicable operating system release, plus two prior releases:
    • Android (Chrome)
    • Apple (Safari)

Applications & Software

For technical assistance, please refer to our Support Manual.

ADA Statement
Med-IQ fully complies with the legal requirements of the ADA and the rules and regulations thereof. If any participant in this educational activity is in need of accommodations, please contact Med-IQ at 443 543 5200.
 
Disclaimer
The information provided through this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

Privacy & Confidentiality
Med-IQ is committed to honoring your privacy and protecting any personal information you choose to share with us. For detailed information about our privacy policy, please visit: www.med-iq.com/privacy-policy.html.

Acknowledgment of Commercial Support
This activity is supported by an educational grant from Genentech.

Copyright
© 2019 Med-IQ, Inc.

Unless otherwise indicated, photographed subjects who appear within the content of this activity or on artwork associated with this activity are models; they are not actual patients or doctors.

Need help? If you need to speak with a member of our team, please call (toll-free) 866 858 7434 or email info@med-iq.com. For technical assistance, please refer to our support manual.